OM Stock Overview
A medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Outset Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$6.37 |
| 52 Week Low | US$0.44 |
| Beta | 1.95 |
| 11 Month Change | 36.07% |
| 3 Month Change | 34.20% |
| 1 Year Change | -85.25% |
| 33 Year Change | -98.39% |
| 5 Year Change | n/a |
| Change since IPO | -98.70% |
Recent News & Updates
Further Upside For Outset Medical, Inc. (NASDAQ:OM) Shares Could Introduce Price Risks After 32% Bounce
Nov 08
Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27%
Sep 24Recent updates
Further Upside For Outset Medical, Inc. (NASDAQ:OM) Shares Could Introduce Price Risks After 32% Bounce
Nov 08Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27%
Sep 24Outset Medical, Inc. (NASDAQ:OM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 11Outset Medical, Inc. (NASDAQ:OM) Stock Rockets 25% But Many Are Still Ignoring The Company
Jul 17Outset Medical: Expecting Accelerated Growth And Reduced Cash Burn Going Forward
May 28Outset Medical, Inc.'s (NASDAQ:OM) CEO Compensation Is Looking A Bit Stretched At The Moment
May 23Investors Still Aren't Entirely Convinced By Outset Medical, Inc.'s (NASDAQ:OM) Revenues Despite 30% Price Jump
May 10Not Many Are Piling Into Outset Medical, Inc. (NASDAQ:OM) Stock Yet As It Plummets 29%
Feb 14Outset Medical, Inc.'s (NASDAQ:OM) Earnings Haven't Escaped The Attention Of Investors
Jun 09Outset Medical: Tablo Ship Hold A Key Overhang To Unlock Risk Capital
Sep 20Outset Medical awarded VA contract for hemodialysis
Aug 15Outset Medical jumps 24% after 2Q results as FDA clears hemodialysis system
Aug 01Outset Medical: Margins Leave No Tangible Value Flow, Pricing 18% Downside
Jul 06Shareholder Returns
| OM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.2% | -1.2% | -2.1% |
| 1Y | -85.3% | 22.4% | 29.6% |
Return vs Industry: OM underperformed the US Medical Equipment industry which returned 22.4% over the past year.
Return vs Market: OM underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| OM volatility | |
|---|---|
| OM Average Weekly Movement | 16.5% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 480 | Leslie Trigg | www.outsetmedical.com |
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform.
Outset Medical, Inc. Fundamentals Summary
| OM fundamental statistics | |
|---|---|
| Market cap | US$41.60m |
| Earnings (TTM) | -US$140.94m |
| Revenue (TTM) | US$114.73m |
0.4x
P/S Ratio-0.3x
P/E RatioIs OM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OM income statement (TTM) | |
|---|---|
| Revenue | US$114.73m |
| Cost of Revenue | US$79.20m |
| Gross Profit | US$35.53m |
| Other Expenses | US$176.47m |
| Earnings | -US$140.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 30.97% |
| Net Profit Margin | -122.84% |
| Debt/Equity Ratio | 412.3% |
How did OM perform over the long term?
See historical performance and comparison